口服普萘洛尔治疗婴幼儿鼻部血管瘤临床疗效评价

Efficacy and safety of oral propranolol for the treatment of infantile hemangiomas in the noses

目的 :评价口服普萘洛尔治疗婴幼儿鼻部血管瘤的临床疗效和安全性。方法 :2013年3月—2015年3月,对确诊为婴幼儿鼻部血管瘤的29例患儿采用口服普萘洛尔2.0 mg/(kg·d)治疗,分2次口服。每3~4周复诊1次,定期拍照,动态观察血管瘤的大小、质地、颜色变化,随时处理治疗过程中的不良反应,根据Achauer疗效判定标准进行疗效评价。结果:29例患儿平均口服普萘洛尔6个月。疗效Ⅰ级(差)0例,Ⅱ级(中)2例,Ⅲ级(好)9例,Ⅳ级(优)18例;2例患儿出现轻度腹泻,2例出现睡眠障碍,未发生严重不良反应。结论:口服普萘洛尔治疗婴幼儿鼻部血管瘤起效快,疗效好,不良反应轻微,可作为首选方法。

PURPOSE ： To estimate the efficacy and safety of oral propranolol for the treatment of infantile hemangiomas in the noses. METHODS ： From March, 2013 to March, 2015, 29 infantile hemangiomas in the noses were treated with oral propranolol at a dose of 2.0 mg/（kg·d）, divided into 2 times. The changes of the tumor size, texture and color were monitored and recorded at a regular interval. The adverse reactions after medication were observed and managed accordingly. The efficacy was evaluated using Achauer＇s system. RESULTS ： The average mediation duration was 6 months. The overall response was gradeⅡ in 2 patients, grade Ⅲ in 9 patients, grade Ⅳ in 18 patients. Adverse reactions were observed in 2 patients, including mild diarrhea and sleep disturbance. CONCLUSION S： Oral propranolol is effective and safe for the treatment of infantile hemangiomas in the noses, and the adverse reaction is minimal.